絞り込み

16642

広告

「人文科学のみは除外」規定、科学技術基本法から削除へ (朝日新聞)

[PR] 科学技術基本法が、対象分野を「科学技術」に絞り、「人文科学のみに係るものを除く」としている規定をやめようという議論が本格化している。人工知能(AI)や...

  1. 90%脂肪のケトン食、インフル防ぐ? 免...
  2. 男女共同参画推進のための学び・キャリア形...
  3. [医学] 食べずにはいられなくする衝動性...
  4. [医学] 含有カロリー消費に要する運動量...

ニュース一覧

スターを付ける スターを付ける     (147view , 0users)

Full Text Sources

Medical

Miscellaneous

Other Literature Sources

Background Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1 and 2 study in relapsed multiple myeloma. Methods We randomly assigned 792 patients with relapsed multiple myeloma to carfilzomib with lenalidomide and dexamethasone (carfilzomib group) or lenalidomide and dexamethasone alone (control group). The primary end point was progression-free survival. Results Progression-free survival was significantly improved with carfilzomib (median, 26.3 months, vs. 17.6 months in the control group; hazard ratio for progression or death, 0.69; 95% confidence interval [CI], 0.57 to 0.83; P=0.0001). The median overall survival was not reached in either group at the interim analysis. The Kaplan-Meier 24-month overall survival rates were 73.3% and 65.0% in the carfilzomib and control groups, respectively (hazard ratio for death, 0.79; 95% CI, 0.63 to 0.99; P=0.04). The rates of overall response (partial response or better) were 87.1% and 66.7% in the carfilzomib and control groups, respectively (P<0.001; 31.8% and 9.3% of patients in the respective groups had a complete response or better; 14.1% and 4.3% had a stringent complete response). Adverse events of grade 3 or higher were reported in 83.7% and 80.7% of patients in the carfilzomib and control groups, respectively; 15.3% and 17.7% of patients discontinued treatment owing to adverse events. Patients in the carfilzomib group reported superior health-related quality of life. Conclusions In patients with relapsed multiple myeloma, the addition of carfilzomib to lenalidomide and dexamethasone resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk-benefit profile. (Funded by Onyx Pharmaceuticals; ClinicalTrials.gov number, NCT01080391 .).
PMID: 25482145 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード